Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free LABT Stock Alerts

This company recently went public with an IPO on Thursday, April 23rd 2026. They issued 4,689,177 shares at $0.00 per share. We will continue to update data for LABT as it becomes available.

Lakewood-Amedex Biotherapeutics (LABT) Competitors

$3.10 -0.16 (-4.91%)
Closing price 04:00 PM Eastern
Extended Trading
$3.12 +0.02 (+0.65%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LABT vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you be buying Lakewood-Amedex Biotherapeutics stock or one of its competitors? The main competitors of Lakewood-Amedex Biotherapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does Lakewood-Amedex Biotherapeutics compare to Ainos?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Ainos (NASDAQ:AIMDW) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A
Ainos$124.16KN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Ainos. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Ainos Neutral

Summary

Lakewood-Amedex Biotherapeutics and Ainos tied by winning 1 of the 2 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Alvotech?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Alvotech (NASDAQ:ALVOW) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Alvotech. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Alvotech. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Alvotech Neutral

Summary

Lakewood-Amedex Biotherapeutics and Alvotech tied by winning 1 of the 2 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Aravive?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Aravive (NASDAQ:ARAV) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Aravive.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A
Aravive$6.99M0.42-$66.21M-$0.90N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Aravive. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Aravive Neutral

Summary

Aravive beats Lakewood-Amedex Biotherapeutics on 3 of the 4 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Lakewood-Amedex Biotherapeutics N/A N/A N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Lakewood-Amedex Biotherapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A

Summary

Lakewood-Amedex Biotherapeutics beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Lakewood-Amedex Biotherapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-3,650.39% -44.92% -39.57%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

In the previous week, Avidity Biosciences and Avidity Biosciences both had 1 articles in the media. Avidity Biosciences' average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Avidity Biosciences Neutral
Lakewood-Amedex Biotherapeutics Neutral

Avidity Biosciences currently has a consensus target price of $69.42, indicating a potential upside of 437.73%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
Lakewood-Amedex Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Avidity Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$18.62MN/A-$322.30MN/AN/A
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A

Summary

Avidity Biosciences beats Lakewood-Amedex Biotherapeutics on 5 of the 8 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABT vs. The Competition

Export
MetricLakewood-Amedex BiotherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market CapN/A$889.45M$4.21B$11.87B
Dividend YieldN/A4.84%5.61%5.21%
P/E RatioN/A1.7123.4028.48
Price / SalesN/A120.50186.6860.89
Price / CashN/A20.0752.8236.52
Price / BookN/A7.6038.316.67
Net IncomeN/A-$4.80M$114.66M$332.64M
7 Day Performance-20.31%-0.05%1.21%2.01%
1 Month PerformanceN/A5.50%5.51%9.19%
1 Year PerformanceN/A30.96%18.68%39.59%

Lakewood-Amedex Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABT
Lakewood-Amedex Biotherapeutics
N/A$3.10
-4.9%		N/AN/A$0.00N/AN/A5
AIMDW
Ainos
N/A$0.11
flat		N/AN/A$0.00$124.16KN/A40
ALVOW
Alvotech
N/A$0.21
-18.2%		N/AN/A$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel